Overview

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

Status:
RECRUITING
Trial end date:
2030-09-01
Target enrollment:
Participant gender:
Summary
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.
Phase:
PHASE1
Details
Lead Sponsor:
Navy General Hospital, Beijing
Treatments:
venetoclax